| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.4 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |